Doctors Revision

Antipsychotic Drugs: Pharmacology, Clinical Use and Safe Monitoring

By /

Antipsychotic Drugs: Individual Medicines, Doses, Adverse Effects and Safe Monitoring

Antipsychotics are used mainly for schizophrenia-spectrum psychosis, acute mania and selected severe behavioural disturbance after medical causes have been assessed. Their therapeutic effect comes chiefly from dopamine D2 antagonism or partial agonism; their harms arise because dopamine, histamine, muscarinic and alpha1 receptors also regulate movement, prolactin, alertness, metabolism and autonomic function. The doses below are common adult teaching ranges—not personal prescriptions. Always verify the diagnosis, product, local mental-health protocol, pregnancy status, organ function, ECG risk and drug interactions.

Learning outcomes

  • Use receptor pharmacology to predict benefit and adverse effects.
  • Choose between typical and atypical agents using individual drug risks, not only class labels.
  • Recognise acute dystonia, akathisia, parkinsonism, tardive dyskinesia, NMS, hyperprolactinaemia and metabolic toxicity.
  • Plan baseline and ongoing physical monitoring, including the special requirements for clozapine.

1. Dopamine pathways: why D2 blockade helps and harms

Pathway Effect of D2 blockade Clinical meaning
Mesolimbic Reduces dopamine signalling. Reduces hallucinations, delusions and thought disorganisation.
Nigrostriatal Interferes with movement pathways. Acute dystonia, akathisia, parkinsonism and tardive dyskinesia.
Tuberoinfundibular Removes dopamine’s restraint on prolactin. Galactorrhoea, sexual dysfunction, menstrual disturbance, infertility and bone-risk effects.
Mesocortical Strong blockade may be unhelpful for cognition/negative symptoms. Drug choice should consider function, not positive symptoms alone.

2. Class pattern—then individualise

First-generation / typical

  • High potency: haloperidol, fluphenazine—more D2 blockade and EPS/prolactin risk.
  • Low potency: chlorpromazine—more sedation, antimuscarinic effects and postural hypotension.

Second-generation / atypical

  • Serotonin–dopamine pharmacology often means less EPS at usual doses, but not zero EPS.
  • Metabolic, prolactin, cardiac, anticholinergic and haematological risks differ markedly by agent.

Before starting any agent

  • Exclude delirium, hypoglycaemia, hypoxia, infection, intoxication/withdrawal, pain and neurological disease.
  • Record target symptoms, capacity/consent, suicide/violence risk, medicines and physical baseline.

3. Individual antipsychotic drug cards

Chlorpromazine

Mechanism and receptor profile

  • Low-potency first-generation antipsychotic: D2 antagonism with substantial H1, M1 and alpha1 blockade.
  • Less EPS than high-potency typicals at comparable clinical effect, but more sedation, hypotension and anticholinergic toxicity.

Formulations and common adult teaching doses

  • Oral tablets/liquid and IM injection; product availability varies.
  • For psychosis, a common oral start is 25–50 mg two or three times daily, then gradual titration; total daily ranges vary widely by setting and local protocol.

Indications

  • Schizophrenia-spectrum psychosis and acute mania where appropriate.
  • Selected severe agitation, nausea/vomiting or intractable hiccups only under indication-specific guidance.

Common side effects

  • Sedation: H1 blockade impairs alertness and increases falls risk.
  • Dry mouth, constipation and blurred vision: antimuscarinic action.
  • Postural dizziness: alpha1 blockade lowers BP on standing.
  • Weight gain: appetite/metabolic receptor effects may be substantial.

Serious adverse effects

  • QT prolongation/arrhythmia: risk rises with high dose, electrolyte disturbance and other QT drugs.
  • Cholestatic jaundice: new pruritus, dark urine or jaundice needs urgent review.
  • NMS or seizures: rare but life-threatening dopamine-blockade complications.

Contraindications and cautions

  • Caution in dementia/frailty, cardiovascular disease, glaucoma, prostatic obstruction, constipation/ileus, seizure disorder and hepatic impairment.
  • In Parkinson disease or Lewy-body dementia, antipsychotic sensitivity and motor worsening can be severe.

Interactions

  • Alcohol, opioids, benzodiazepines and sedatives add CNS/respiratory depression.
  • Other anticholinergics add retention/ileus; QT-prolonging drugs increase arrhythmia risk.

Monitoring and counselling

  • Monitor BP sitting/standing, sedation/falls, bowel/bladder function, weight and ECG when risk factors exist.
  • Advise slow standing, avoid alcohol/driving until response is known, and report fever/rigidity, jaundice, palpitations or severe constipation.

Haloperidol

Mechanism and receptor profile

  • High-potency first-generation D2 antagonist with relatively little antimuscarinic or alpha1 activity.
  • Strong D2 blockade gives reliable control of positive psychosis but high EPS and hyperprolactinaemia risk.

Formulations and common adult teaching doses

  • Oral tablets/liquid, short-acting IM and long-acting decanoate injections exist.
  • Common oral adult starts for psychosis are 0.5–2 mg once or twice daily; acute IM regimens and depot conversion must follow specialist/local protocol with ECG risk review.

Indications

  • Schizophrenia-spectrum psychosis, acute agitation when appropriate, mania and selected delirium pathways with careful medical assessment.
  • Choice in agitation must never replace de-escalation, diagnosis and treatment of cause.

Common side effects

  • Acute dystonia: painful neck/jaw/eye spasm can occur within hours–days, especially in young men.
  • Akathisia: unbearable inner restlessness/pacing may be mistaken for worsening agitation.
  • Parkinsonism: tremor, rigidity, bradykinesia and masked face reflect nigrostriatal D2 blockade.
  • Hyperprolactinaemia: causes galactorrhoea, sexual dysfunction and menstrual disturbance.

Serious adverse effects

  • QT prolongation/torsades: ECG risk increases with high dose, IV use, low K/Mg or other QT-prolonging drugs.
  • NMS: fever, lead-pipe rigidity, autonomic instability, altered mental state and raised CK are an emergency.
  • Tardive dyskinesia: late, potentially persistent involuntary oro-facial/limb movements.

Contraindications and cautions

  • Caution/avoidance in Parkinson disease, Lewy-body dementia, known long-QT/arrhythmia, severe electrolyte disturbance and seizure disorder.
  • Older adults with dementia have increased mortality/cerebrovascular risk with antipsychotics—use only when justified and reviewed.

Interactions

  • QT-prolonging antiarrhythmics, macrolides, fluoroquinolones, methadone and some antidepressants add torsades risk.
  • Levodopa/dopamine agonists oppose efficacy and may worsen parkinsonism; CNS depressants increase sedation.

Monitoring and counselling

  • Document an EPS baseline, check pulse/BP, ECG/electrolytes when indicated, and ask about restlessness, rigidity, fever and involuntary movements every review.
  • Urgent review is required for eye/neck spasm, severe restlessness, collapse/palpitations, fever with rigidity or swallowing/breathing difficulty.

Risperidone

Mechanism and receptor profile

  • Second-generation antipsychotic with D2 and 5-HT2A antagonism; EPS becomes more likely as dose rises.
  • Notable for comparatively high and persistent prolactin elevation among atypical antipsychotics.

Formulations and common adult teaching doses

  • Oral tablets, solution, orodispersible tablets and long-acting injectables exist.
  • For adult schizophrenia, start commonly at 1–2 mg/day, titrating gradually; common range 2–6 mg/day. Long-acting preparations have different initiation/oral-overlap rules.

Indications

  • Schizophrenia-spectrum psychosis and acute mania; other licensed uses vary with age and local protocol.
  • Long-acting injection may support adherence after an effective/tolerated oral trial.

Common side effects

  • Hyperprolactinaemia: D2 blockade may cause amenorrhoea, galactorrhoea, erectile dysfunction, reduced libido and infertility.
  • EPS/akathisia: dose-related, especially at higher doses.
  • Weight gain and sedation: usually less than olanzapine/clozapine but still clinically important.
  • Postural dizziness: alpha1 blockade can lower BP.

Serious adverse effects

  • Persistent hyperprolactinaemia: hypogonadism can reduce bone density over time.
  • Stroke/mortality warning in dementia-related psychosis: avoid casual use for non-psychotic behaviour.
  • NMS, severe EPS or QT risk: uncommon but serious class events.

Contraindications and cautions

  • Use caution in Parkinson/Lewy-body disease, epilepsy, cardiovascular disease, diabetes, hyperprolactinaemia history and renal/hepatic impairment.
  • Assess pregnancy/lactation, fertility concerns and prior prolactin-sensitive disease individually.

Interactions

  • Fluoxetine/paroxetine may increase exposure through CYP2D6 inhibition; carbamazepine may reduce concentrations.
  • Other dopamine blockers add EPS/prolactin effects; alcohol/sedatives add impairment.

Monitoring and counselling

  • Monitor weight/BMI, waist, BP, glucose/HbA1c, lipids, prolactin-related symptoms, menstrual/sexual function and EPS.
  • Do not stop abruptly; report breast discharge, missed periods, severe stiffness/fever, persistent restlessness or new involuntary movements.

Paliperidone

Mechanism and receptor profile

  • Active metabolite of risperidone; D2/5-HT2A antagonist with similar prolactin and EPS concerns.
  • More renally eliminated than risperidone, which matters in dose selection.

Formulations and common adult teaching doses

  • Extended-release oral tablets and several long-acting injectable formulations exist.
  • Oral extended-release commonly begins at 3–6 mg once daily; depot loading/maintenance schedules must follow the exact product and renal-function protocol.

Indications

  • Schizophrenia-spectrum disorders and selected schizoaffective presentations where locally indicated.

Common side effects

  • Prolactin elevation: same endocrine/sexual/bone consequences as risperidone.
  • Insomnia, akathisia or parkinsonism: dopamine blockade effects.
  • Weight gain and tachycardia: need routine review.

Serious adverse effects

  • QT prolongation: risk is higher with electrolyte abnormality or QT co-medication.
  • NMS/tardive dyskinesia: rare but potentially severe.
  • Injection-site/long-duration exposure: adverse effects of depot treatment cannot be rapidly withdrawn.

Contraindications and cautions

  • Adjust/avoid in significant renal impairment according to product limits.
  • Use caution in Parkinson/Lewy-body disease, seizure disorder, cardiovascular disease and dementia-related psychosis.

Interactions

  • Other QT-prolonging or dopamine-blocking medicines add risk.
  • Avoid confusing depot formulations: each has distinct loading, oral-overlap and injection-site requirements.

Monitoring and counselling

  • Review renal function, metabolic measures, ECG risk, prolactin symptoms, EPS and depot appointment adherence.
  • Teach the patient to report injection reactions, breast/menstrual/sexual symptoms, fever/rigidity or syncope.

Olanzapine

Mechanism and receptor profile

  • Second-generation D2/5-HT2A antagonist with prominent H1, M1 and metabolic receptor effects.
  • Lower usual EPS/prolactin risk than haloperidol or risperidone, but high metabolic risk.

Formulations and common adult teaching doses

  • Oral tablets, orodispersible tablets, short-acting IM and long-acting pamoate injection exist.
  • Oral treatment commonly starts 5–10 mg once daily; many adults use 10–20 mg daily depending on indication/response. Depot use requires its own observation protocol.

Indications

  • Schizophrenia-spectrum psychosis and bipolar mania/maintenance depending on guideline and formulation.
  • Combination use for bipolar depression or treatment-resistant depression is indication-specific and specialist-led.

Common side effects

  • Weight gain/increased appetite: can be rapid and substantial.
  • Hyperglycaemia and dyslipidaemia: metabolic changes may develop even without dramatic weight gain.
  • Sedation: H1 blockade impairs alertness.
  • Dry mouth/constipation: antimuscarinic action.

Serious adverse effects

  • Diabetes or diabetic ketoacidosis: thirst, polyuria, vomiting or confusion require urgent assessment.
  • Severe metabolic syndrome/cardiovascular risk: requires active prevention and monitoring.
  • Post-injection delirium/sedation syndrome: rare but serious risk with depot pamoate; mandatory observation procedures apply.

Contraindications and cautions

  • Use caution in diabetes/prediabetes, obesity, dyslipidaemia, liver disease, constipation/ileus, glaucoma and seizure disorder.
  • Consider lower starting dose in frail patients or those prone to hypotension/sedation.

Interactions

  • Smoking induces CYP1A2 and can lower exposure; stopping smoking can raise levels—review doses and toxicity.
  • Alcohol/sedatives add impairment; anticholinergics increase retention/ileus risk.

Monitoring and counselling

  • Record weight/BMI/waist, BP, fasting glucose or HbA1c and lipids at baseline and periodically; ask about diet, thirst, urination and constipation.
  • Do not alter smoking abruptly without informing the prescriber; seek urgent help for severe vomiting, confusion, fever/rigidity or profound sedation.

Quetiapine

Mechanism and receptor profile

  • Second-generation D2/5-HT2A antagonist with strong H1 and alpha1 effects; relatively low D2 occupancy at usual doses gives lower EPS tendency.
  • Sedation and postural hypotension are often more clinically important than EPS.

Formulations and common adult teaching doses

  • Immediate-release and extended-release oral tablets; not interchangeable without reviewing regimen.
  • For psychosis, common starts are 25–50 mg at night with gradual titration; therapeutic ranges often 300–800 mg/day depending on indication/formulation.

Indications

  • Schizophrenia and bipolar disorder across acute mania, depression or maintenance according to formulation/guideline.
  • Low-dose off-label use for insomnia is not routine benign prescribing and carries metabolic/falls risks.

Common side effects

  • Somnolence: H1 blockade can be intense early in treatment.
  • Postural hypotension/tachycardia: alpha1 blockade and titration effects.
  • Weight gain and dyslipidaemia: require active metabolic review.
  • Dry mouth/constipation: anticholinergic effects.

Serious adverse effects

  • Falls/syncope: sedation and orthostasis are hazardous in older adults.
  • Hyperglycaemia/metabolic syndrome: monitor even at apparently “sleep” doses.
  • QT risk, NMS and severe neutropenia: rare but important.

Contraindications and cautions

  • Caution in cardiovascular disease, diabetes/obesity, epilepsy, hepatic impairment, glaucoma, constipation/retention and fall risk.
  • Assess for sleep apnoea, alcohol/opioid use and daytime safety before sedating treatment.

Interactions

  • Strong CYP3A4 inhibitors raise levels; inducers such as carbamazepine can lower them substantially.
  • Alcohol, opioids, benzodiazepines and other sedatives increase falls/respiratory impairment.

Monitoring and counselling

  • Monitor sedation, standing BP/pulse, falls, weight, glucose/lipids, bowel function and mood/suicide risk where indicated.
  • Take as prescribed, rise slowly and avoid driving/alcohol until effects are known; report syncope, severe constipation or high glucose symptoms.

Clozapine

Mechanism and receptor profile

  • Multi-receptor atypical antipsychotic with relatively weak D2 blockade and important 5-HT2A, H1, M1 and alpha1 effects.
  • Most effective option for treatment-resistant schizophrenia and reduces recurrent suicidal behaviour in selected patients, but requires specialist monitoring infrastructure.

Formulations and common adult teaching doses

  • Oral tablets, orally disintegrating tablets and suspension are available.
  • Common initiation is 12.5 mg once or twice daily, increasing slowly; many patients use 300–450 mg/day divided, with higher doses only under specialist monitoring. Re-start after interruption requires re-titration.

Indications

  • Treatment-resistant schizophrenia after adequate trials of other antipsychotics.
  • Specialist use for persistent suicidal behaviour in schizophrenia/schizoaffective disorder where approved.

Common side effects

  • Marked sedation and weight gain: H1/metabolic effects.
  • Hypersalivation: paradoxical and distressing, often nocturnal.
  • Constipation: common but never trivial with clozapine.
  • Postural dizziness/tachycardia: alpha1 and autonomic effects during titration.

Serious adverse effects

  • Severe neutropenia/agranulocytosis: infection risk can be fatal; baseline and scheduled ANC monitoring are mandatory under the applicable monitoring programme.
  • Myocarditis/cardiomyopathy: chest pain, dyspnoea, fever, persistent tachycardia, hypotension or flu-like illness require urgent cardiac assessment.
  • Severe constipation/ileus: may rapidly progress to obstruction, perforation or death; actively ask about bowels at every contact.
  • Seizures: dose-related risk, increased by rapid titration or interacting medicines.

Contraindications and cautions

  • Do not start without reliable blood monitoring and specialist follow-up. Consider prior clozapine neutropenia, uncontrolled epilepsy, serious cardiac disease, severe constipation/ileus and inability to adhere to monitoring.
  • Smoking changes, infection and interacting drugs can sharply alter plasma concentrations.

Interactions

  • Smoking cessation and CYP1A2 inhibitors such as fluvoxamine/ciprofloxacin can raise levels; smoking induction can lower levels.
  • Other marrow-suppressing drugs, sedatives, anticholinergics and seizure-threshold-lowering drugs require careful specialist review.

Monitoring and counselling

  • Baseline and scheduled ANC, weight/BMI, waist, BP/pulse, glucose/lipids, bowel pattern, seizure risk and myocarditis surveillance according to local programme.
  • Urgently report fever, sore throat, infection symptoms, chest pain, shortness of breath, fainting, seizure or no bowel motion/abdominal pain. Never stop/restart casually.

Aripiprazole

Mechanism and receptor profile

  • D2/D3 partial agonist with 5-HT1A partial agonism and 5-HT2A antagonism—sometimes described as dopamine-system stabilisation.
  • Usually lower metabolic, prolactin and sedation burden than several alternatives, but akathisia and activation are characteristic.

Formulations and common adult teaching doses

  • Oral tablets, orodispersible tablets/liquid and long-acting injectable products exist.
  • Common oral adult start is 10–15 mg once daily; usual range 10–30 mg/day. Depot initiation/oral overlap follows exact product protocol.

Indications

  • Schizophrenia and bipolar I disorder; adjunctive major-depression use and other indications are product- and guideline-specific.

Common side effects

  • Akathisia/restlessness: an activated, uncomfortable inability to stay still may occur early.
  • Insomnia, nausea and headache: common tolerability effects.
  • Less prolactin/weight effect: useful comparative feature, but metabolic monitoring is still required.

Serious adverse effects

  • Impulse-control problems: new gambling, shopping, binge eating or sexual behaviour can be severe and needs active questioning.
  • NMS, tardive dyskinesia or suicidality/mood activation: rare but clinically important.
  • Orthostasis or arrhythmia: assess in vulnerable patients.

Contraindications and cautions

  • Caution with previous severe akathisia, bipolar mixed/manic activation, impulse-control vulnerability, seizures, cardiovascular disease and dementia-related psychosis.
  • Do not assume low metabolic risk means no physical monitoring.

Interactions

  • Strong CYP2D6/CYP3A4 inhibitors may require dose reduction; strong CYP3A4 inducers may lower exposure or make certain depot formulations unsuitable.
  • Alcohol and sedatives increase impairment; other dopamine-active medicines require deliberate rationale.

Monitoring and counselling

  • Ask specifically about restlessness, sleep, mood elevation, gambling/shopping/sexual behaviour, weight and EPS.
  • Seek review early for unbearable agitation, new risky impulses, fever/rigidity, fainting or involuntary movements.

4. Movement and life-threatening adverse effects

Problem Timing/presentation Immediate response
Acute dystonia Hours–days: torticollis, jaw spasm, oculogyric crisis, laryngospasm. Urgent assessment; protect airway; give protocol-directed antimuscarinic treatment and review agent/dose.
Akathisia Days–weeks: inner restlessness, pacing, inability to sit. Do not call it “agitation” and escalate antipsychotic blindly; review dose/agent and treat by protocol.
Drug-induced parkinsonism Weeks–months: rigidity, tremor, bradykinesia. Review reduction/switch; distinguish from primary Parkinson disease.
Tardive dyskinesia Months–years: late involuntary facial/tongue/limb movements. Recognise early, document severity, reduce exposure/switch with specialist input; may persist.
NMS Fever, lead-pipe rigidity, autonomic instability, altered state, raised CK. Stop suspected agent; ABC, cooling, IV fluids, CK/renal monitoring and urgent critical-care/psychiatry support.

Neuroleptic malignant syndrome is a medical emergency

  • Consider NMS after starting/increasing dopamine-blocking treatment or after withdrawal of dopaminergic therapy.
  • Stop the culprit, assess airway/ventilation/circulation, cool safely, give IV fluids, check CK, renal function/electrolytes and exclude sepsis/serotonin syndrome/malignant hyperthermia.
  • Do not restart an antipsychotic until specialist review, recovery and a documented risk–benefit plan.

5. Physical-health monitoring and counselling

Baseline Every review Periodic tests
  • Weight/BMI and waist.
  • BP/pulse; personal/family cardiac history.
  • Glucose/HbA1c and lipids.
  • EPS/tardive baseline, prolactin/sexual history, bowel function.
  • ECG if cardiac/QT risk, interacting medicine or agent requires it.
  • Target symptoms, adherence and relapse risk.
  • EPS, sedation, falls, mood/suicide risk and substance use.
  • Constipation, urine difficulty, menstrual/sexual/breast symptoms.
  • Diet, activity, smoking status and adverse effects.
  • Weight/BP and metabolic tests at guideline intervals.
  • ECG/electrolytes when dose/risk changes.
  • ANC and clozapine-specific monitoring exactly as programme requires.

Clinical safety reminders

  • Use the lowest effective dose and a single clear target. Avoid unnecessary antipsychotic polypharmacy.
  • A long-acting injection helps adherence only after establishing oral efficacy/tolerability and arranging follow-up.
  • Never abruptly stop a stable medicine without a plan unless an emergency reaction requires it; abrupt stopping can precipitate relapse/withdrawal.
  • Explain patient red flags: fever/rigidity, severe restlessness, abnormal movements, syncope/palpitations, severe constipation, high glucose symptoms, infection symptoms on clozapine, and suicidal thoughts.

Further study

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top